Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and
other agents. There is a factor called ISG15 which might help doctors better identify
patients with advanced non-small cell lung cancer (NSCLC) whose tumors may be more sensitive
to the drug called Irinotecan. This factor is elevated in roughly 30% of NSCLC cases.
Irinotecan is an agent that inhibits the enzyme called topoisomerase I that is involved in
cell growth, and it has been FDA approved for 17 years for another type of cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New Mexico Cancer Care Alliance
Collaborators:
Lovelace Respiratory Research Institute University of New Mexico Cancer Center